Literature DB >> 25533812

Natural inhibitors of PI3K/AKT signaling in breast cancer: emphasis on newly-discovered molecular mechanisms of action.

Yaghoub Safdari1, Masoumeh Khalili2, Mohammad Ali Ebrahimzadeh3, Yaghoub Yazdani4, Safar Farajnia5.   

Abstract

Epidermal growth factor receptor (EGFR) plays a critical role in the initiation and progression of a variety of human cancers, including breast cancer. An important signaling pathway downstream of EGFR is the PI3K/AKt pathway, which regulates cellular processes as diverse as cell growth, survival, proliferation and migration. Deregulated activity of this pathway may lead to uncontrolled cell growth, survival, migration and invasion, contributing to tumor formation. In this review, we evaluate natural compounds that, in vitro (breast cancer cell lines) and/or in vivo (animal model, clinical) studies, suppress breast cancer cells or tumors mainly by suppressing the PI3K/AKT signaling pathway. The effect of these compounds on cell cycle arrest, inhibition of cell migration and invasion, tumor angiogenesis and metastasis in breast cancer are discussed.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AKT; Ascofuranone (PubChem CID: 6434242); BYL-719 (PubChem CID: 56649450); Breast cancer; CDRI 85-287 (PubChem CID: 159508); Fenretinide: (PubChem CID: 5288209); Isoliquiritigenin (PubChem CID: 638278); Natural inhibitors; PI3K; Platycodin D (PubChem CID: 162859); Quercetin (PubChem CID: 5280343); Thymoquinone (PubChem CID:10281); Wogonin (PubChem CID: 5281703)

Mesh:

Substances:

Year:  2014        PMID: 25533812     DOI: 10.1016/j.phrs.2014.12.004

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  29 in total

1.  PEBP4 promoted the growth and migration of cancer cells in pancreatic ductal adenocarcinoma.

Authors:  Dexiang Zhang; Yuedi Dai; Yuankun Cai; Tao Suo; Han Liu; Yueqi Wang; Zhijian Cheng; Houbao Liu
Journal:  Tumour Biol       Date:  2015-08-27

2.  Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations.

Authors:  Yong-Xia Bao; Xiao-Dan Zhao; Hong-Bin Deng; Chang-Lian Lu; Yang Guo; Xing Lu; Li-Li Deng
Journal:  Cell Oncol (Dordr)       Date:  2016-03-25       Impact factor: 6.730

3.  PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway.

Authors:  Ju Zhou; Saber Imani; Marzieh Dehghan Shasaltaneh; Shuguang Liu; Tao Lu; Junjiang Fu
Journal:  Mol Biol Rep       Date:  2021-11-23       Impact factor: 2.316

Review 4.  Myeloid-derived suppressor cells in B cell malignancies.

Authors:  Yaghoub Yazdani; Mousa Mohammadnia-Afrouzi; Mehdi Yousefi; Enayat Anvari; Ghasem Ghalamfarsa; Hadi Hasannia; Sanam Sadreddini; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2015-09-02

5.  Oncogenic activity of insulin in the development of non-small cell lung carcinoma.

Authors:  Jie Jiang; Hong-Yue Ren; Guo-Jun Geng; Yan-Jun Mi; Yu Liu; Ning Li; Shu-Yu Yang; Dong-Yan Shen
Journal:  Oncol Lett       Date:  2017-11-03       Impact factor: 2.967

Review 6.  Advances of wogonin, an extract from Scutellaria baicalensis, for the treatment of multiple tumors.

Authors:  Xue Wu; Haijun Zhang; Jumah Masoud Mohammad Salmani; Rong Fu; Baoan Chen
Journal:  Onco Targets Ther       Date:  2016-05-17       Impact factor: 4.147

7.  SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline.

Authors:  Maxime Guéguinou; Thomas Harnois; David Crottes; Arnaud Uguen; Nadine Deliot; Audrey Gambade; Aurélie Chantôme; Jean Pierre Haelters; Paul Alain Jaffrès; Marie Lise Jourdan; Günther Weber; Olivier Soriani; Philippe Bougnoux; Olivier Mignen; Nicolas Bourmeyster; Bruno Constantin; Thierry Lecomte; Christophe Vandier; Marie Potier-Cartereau
Journal:  Oncotarget       Date:  2016-06-14

8.  Down-regulation of dihydrofolate reductase inhibits the growth of endothelial EA.hy926 cell through induction of G1 cell cycle arrest via up-regulating p53 and p21(waf1/cip1) expression.

Authors:  Zhewei Fei; Yong Gao; Mingke Qiu; Xianqin Qi; Yuxin Dai; Shuqing Wang; Zhiwei Quan; Yingbin Liu; Jingmin Ou
Journal:  J Clin Biochem Nutr       Date:  2016-02-04       Impact factor: 3.114

9.  Status of the Parkinson's disease gene family expression in non-small-cell lung cancer.

Authors:  Quan Xing Liu; Hong Zheng; Xu Feng Deng; Dong Zhou; Ji Gang Dai
Journal:  World J Surg Oncol       Date:  2015-08-07       Impact factor: 2.754

10.  Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer.

Authors:  Jing Chen; Shuzhen Deng; Yifan Zhang; Chaokun Wang; Xiaochen Hu; Dejiu Kong; Gaofeng Liang; Xiang Yuan; Yuanpei Li; Xinshuai Wang
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.